SGLT: A Protein Implicated in Diabetes and Other Diseases (P9239)

Target Name: Sodium-Glucose Cotransporter (SGLT)

NCBI ID: P9239

Sodium-Glucose Cotransporter (SGLT)

Other Name(s): SGLT

SGLT: A Protein Implicated in Diabetes and Other Diseases

Sodium-Glucose Cotransporter (SGLT) (nonspecified subtype) (SGLT) is a protein that is expressed in various tissues and cells in the body. It plays a crucial role in the regulation of glucose metabolism and has been implicated in various diseases, including diabetes. As a result, SGLT has emerged as a drug target and a potential biomarker for several diseases.

SGLT is a type of transmembrane protein that is composed of two main subunits, SGLT1 and SGLT2. SGLT1 is predominantly expressed in the kidneys, while SGLT2 is predominantly expressed in the intestine. Both subunits are involved in the regulation of glucose uptake and utilization. SGLT1 is responsible for the initial uptake of glucose from the gut lumen into the bloodstream, while SGLT2 is responsible for the subsequent translocation of glucose across the intestinal wall into the bloodstream.

SGLT has been shown to play a key role in the regulation of glucose metabolism and has been implicated in the development and progression of several diseases, including type 2 diabetes, obesity, and hypertension. One of the mechanisms through which SGLT contributes to these diseases is its role in modulating the balance between insulin and glucagon signaling. Insulin is a hormone that regulates glucose uptake and utilization, while glucagon is a hormone that regulates glucose release from cells. SGLT has been shown to play a critical role in the regulation of this balance, as it can either increase or decrease the activity of the insulin-sensitive GLUT-1 gene, which encodes a protein that is involved in the uptake of glucose from the gut lumen into the bloodstream.

In addition to its role in modulating insulin and glucagon signaling, SGLT has also been shown to contribute to the development of various diseases by regulating the balance between sodium and glucose in the body. SGLT has been shown to play a critical role in the regulation of sodium and glucose transport in the kidney, as it is expressed in the podocytes of the kidney that are responsible for regulating the reabsorption of sodium and glucose from the urine. SGLT has also been shown to contribute to the regulation of sodium and glucose metabolism in the body by modulating the activity of several enzymes involved in this process, including the sodium-glucose cotransporter (SGLT2), which is responsible for the reabsorption of sodium and glucose from the urine.

SGLT has also been shown to be involved in the regulation of inflammation in the body, which is a key factor in the development of many diseases, including type 2 diabetes and obesity. SGLT has been shown to play a critical role in the regulation of inflammation by modulating the activity of several immune cells and promoting the production of pro-inflammatory cytokines. This contributes to the development of diseases that are characterized by chronic inflammation, such as type 2 diabetes and obesity.

SGLT has also been shown to play a critical role in the regulation of stem cell proliferation and differentiation. Stem cells are a key factor in the development of many diseases, including cancer. SGLT has been shown to play a critical role in the regulation of stem cell proliferation by modulating the activity of several signaling pathways, including the TGF-β pathway. This contributes to the development of diseases that are characterized by the proliferation of stem cells, such as cancer.

In conclusion, Sodium-Glucose Cotransporter (SGLT) (nonspecified subtype) (SGLT) is a protein that is involved in the regulation of glucose metabolism and has been implicated in the development and progression of several diseases. Its role in modulating insulin and glucagon signaling, as well as its contribution to the regulation of sodium and glucose metabolism and inflammation, makes it an attractive drug target and a potential biomarker for several diseases. Further research is needed to fully understand the role of SGLT in these diseases and to develop effective treatments.

Protein Name: Sodium-Glucose Cotransporter (SGLT) (nonspecified Subtype)

The "Sodium-Glucose Cotransporter (SGLT) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Sodium-Glucose Cotransporter (SGLT) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets